Anika Therapeutics, Inc. (NASDAQ: ANIK) is a Healthcare company (Medical - Specialties) with a market capitalization of $172M. The Maz Rating grades it against the other companies in its sector.
Anika Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $12.85, Anika Therapeutics, Inc. trades at 1.4x sales and 1.2x book value, with an EV/EBITDA of 29.5. Over the last twelve months it generated about $124M of revenue and a net loss of $2M. It runs a gross margin of 63.4%, an operating margin of -2.1% and a net margin of -1.4%. It shows return on equity of -1.3%, return on invested capital of -0.4% and a free cash flow yield of 1.3%. On the balance sheet: a debt-to-equity ratio of 0.18 and a current ratio of 3.86. Over the past 52 weeks the share price ranged from $9.01 to $22.88, with a beta of 0.21.
Anika Therapeutics, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 4 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Anika Therapeutics, Inc. (ANIK) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 9.24% / 30% · (Cash+Inv) / Mkt Cap (36m) 16.9% / 30% · Interest income / Revenue 0.00% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 9.24% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 16.9% / 33% · Receivables / Mkt Cap (36m) 9.12% / 49% · Interest income / Revenue 0.00% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 9.24% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 16.9% / 33.33% · Receivables / Mkt Cap (24m) 9.12% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 9.97% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 24.5% / 33.33% · Receivables / Avg Assets (4Q) 13.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 13.0% / 33.33% · (Cash+ST Inv) / Total Assets 23.7% / 33.33% · (Cash+Recv) / Total Assets 36.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Anika Therapeutics, Inc. (ANIK) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Anika Therapeutics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
Anika Therapeutics, Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.